Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Integumen Plc

1 Sep 2020 12:05

Form 8.3 - Integumen Plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Investec Wealth & Investment
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Integumen plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:N/A
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 28th August 2020
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” Yes – Modern Water plc 1st September 2020

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:  
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:26,812,0002.41%  
(2) Cash-settled derivatives:     
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:26,812,0002.41%  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/sale Number of securitiesPrice per unit
N/A – Opening Position Disclosure

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
    

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
N/A

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
N/A

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:1st September 2020
Contact name:Phil Beardwell Chartered FCSI
Telephone number:020 7597 1356

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
28th Apr 20204:37 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSUpdate re COVID 19; confirmed orders; investment
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
18th Mar 202010:22 amRNSDirector/PDMR Shareholding
18th Mar 20207:00 amRNS3 year $3.75m (£3.12m) bacteria prod'n agreement
12th Mar 20202:06 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
26th Feb 20207:00 amRNSLaunch of ecowaterOS; Company Update
7th Feb 20207:00 amRNSIntegumen plc to present at The UK Investor Show
3rd Feb 20207:00 amRNSCommercial & AI partnership with Acumen Software
21st Jan 20207:00 amRNSCooperative Alliance; Trading Update
19th Dec 20197:00 amRNS3-year Rev sharing Framework Ag with Parity Group
16th Dec 20198:43 amRNSDirector/PDMR Shareholdings
9th Dec 201911:05 amRNSPlacing/Subscription to raise £1.368m -replacement
9th Dec 20197:00 amRNSPlacing and subscription to raise £1.368 million
20th Nov 20197:00 amRNSResults of AI water research project
13th Nov 20197:00 amRNSHeads of Terms -Framework Agreement;trading update
7th Nov 20197:00 amRNSMicrobiome and Labskin clone R&D agreements signed
29th Oct 20197:00 amRNSLaunch of ind. Rinodrive AI open-source eco-system
21st Oct 20197:00 amRNSRinocloud subsidiary wins "One To Watch" IT award
8th Oct 201912:34 pmRNSIssue of Equity: Shares in Lieu of Invoice
7th Oct 20197:00 amRNSLabskin signs multi-year service agreement
7th Oct 20197:00 amRNSLabskinAI creates virtual AI psoriasis skin model
11th Sep 20197:00 amRNSInterim Results
5th Sep 20197:00 amRNSLabskin breakthrough clones 16 human skin swabs
2nd Aug 20197:00 amRNSHighlands Nat. Resources agreement with Cellulac
1st Aug 20191:41 pmRNSExercise of Warrants
1st Aug 201911:32 amRNSExercise of Warrants
31st Jul 20194:30 pmRNSResult of AGM
31st Jul 20197:00 amRNSAGM - Trading Update
29th Jul 20197:00 amRNSCollaboration; Expansion of wound care division
19th Jul 20197:00 amRNSLabskinAI:agreementswith global cosmetic companies
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
11th Jul 201910:38 amRNSExercise of Warrants (update)
10th Jul 201912:55 pmRNSExercise of warrants
8th Jul 20197:00 amRNSAGM Notice and Trading Update
28th Jun 20193:03 pmRNSExercise of Warrants
27th Jun 20197:00 amRNSFinal Results
21st Jun 20197:00 amRNSExercise of Warrants
20th Jun 20197:01 amRNSExecutive team and Labskin AI digital hub updates
20th Jun 20197:00 amRNSExercise of Warrants
10th Jun 20197:00 amRNSExercise of Warrant Shares and Call Option Shares
28th May 20197:30 amRNSExercise of Warrants
28th May 20197:00 amRNSNew Labskin AI contracts; additional lab space
21st May 20197:00 amRNSTrading update and Board changes
10th May 201912:19 pmRNSLaunch of Labskin human skin clone tests

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.